Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J boosts litigation settlement reserve by $600mn

This article was originally published in Scrip

Executive Summary

Rumors that emerged in March may be on the mark that Johnson & Johnson could be paying nearly double the $1 billion it reportedly agreed on with the US Department of Justice (DOJ) to settle charges of illegal off-label promotion of the company's schizophrenia and bipolar drug Risperdal (risperidone), with the firm revealing it had set aside an additional $600 million (scripintelligence, 19 March 2012).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts